Want to see MMED full AI Analyst Report?
MMED Stock Chart & Stats
$19.60
$1.18(6.41%)
At close: 4:00 PM EDT
$19.60
$1.18(6.41%)
Day’s Range― - ―
52-Week Range$10.65 - $20.48
Previous Close$19.6
Volume1.63M
Average Volume (3M)1.15M
Market Cap
$5.07B
Enterprise Value$3.46K
Total Cash (Recent Filing)$298.00M
Total Debt (Recent Filing)$145.00M
Price to Earnings (P/E)―
Beta-0.04
Next Earnings
Sep 01, 2026EPS Estimate
0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.10
Shares Outstanding280,842,830
10 Day Avg. Volume1,207,427
30 Day Avg. Volume1,153,027
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)0.94
Price to Sales (P/S)1.09
P/FCF Ratio-8.06
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$21.60Price Target Upside10.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)0.63
Revenue Forecast (FY)$3.42B
Bulls Say, Bears Say
Bulls Say
Revenue Acceleration & Gross MarginSustained 104.9% revenue growth and a 54.2% gross margin reflect strong market adoption and pricing or product mix advantages. Over 2–6 months this top-line momentum and durable gross profitability support scale economics, reinvestment capacity and long-term margin resilience if growth persists.
Conservative Balance SheetLow leverage versus a large equity base provides financial flexibility to fund operations, R&D or M&A without urgent refinancing. This conservative capital structure lowers bankruptcy risk and supports durable capacity to invest through cycles, important over the next several months.
Progress Toward Operating ProfitabilityA shift from negative to a positive ~1.6% operating margin indicates improving cost structure and operational leverage as scale builds. If management sustains this improvement with continued revenue growth, it signals a durable path toward consistent profitability over the medium term.
Bears Say
Widening Net LossesGrowing absolute losses and negative margins reduce retained capital and constrain the firm's ability to fund growth internally. Persisting large net losses over several quarters raises the probability of dilution or strategic retrenchment and points to structural profitability challenges.
Deteriorating Cash GenerationA material reversal to negative operating cash flow and sharply worsening FCF represent rising cash burn. Over a multi-month horizon this elevates funding risk, increases dependence on external capital, and can force slower growth, higher financing costs or dilution if not corrected.
Negative Returns On EquityPersistent negative ROE means capital employed is not generating shareholder value. This structural inability to convert assets and equity into profits undermines long-term investor confidence and signals deeper issues in business economics that must be resolved to sustain growth.
MMED FAQ
What was MiniMed Group, Inc.’s price range in the past 12 months?
MiniMed Group, Inc. lowest stock price was $10.65 and its highest was $20.48 in the past 12 months.
What is MiniMed Group, Inc.’s market cap?
MiniMed Group, Inc.’s market cap is $5.07B.
When is MiniMed Group, Inc.’s upcoming earnings report date?
MiniMed Group, Inc.’s upcoming earnings report date is Sep 01, 2026 which is in 23 days.
How were MiniMed Group, Inc.’s earnings last quarter?
MiniMed Group, Inc. released its earnings results on Jun 03, 2026. The company reported -$0.68 earnings per share for the quarter, missing the consensus estimate of -$0.149 by -$0.531.
Is MiniMed Group, Inc. overvalued?
According to Wall Street analysts MiniMed Group, Inc.’s price is currently Undervalued.
Does MiniMed Group, Inc. pay dividends?
MiniMed Group, Inc. does not currently pay dividends.
What is MiniMed Group, Inc.’s EPS estimate?
MiniMed Group, Inc.’s EPS estimate is 0.1.
How many shares outstanding does MiniMed Group, Inc. have?
MiniMed Group, Inc. has 280,842,830 shares outstanding.
What happened to MiniMed Group, Inc.’s price movement after its last earnings report?
MiniMed Group, Inc. reported an EPS of -$0.68 in its last earnings report, missing expectations of -$0.149. Following the earnings report the stock price went up 15.935%.
Which hedge fund is a major shareholder of MiniMed Group, Inc.?
Currently, no hedge funds are holding shares in MMED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MiniMed Group, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.60 (10.20% Upside)
$21.60 (10.20% Upside)
Blogger Sentiment
Bullish
MMED Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.3%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
10.21%
Trailing 12-Months
Company Description
MiniMed Group, Inc.
MiniMed Group, Inc. specializes in designing, producing, and distributing a broad spectrum of medical technologies and solutions aimed at effective diabetes management. The company's diverse portfolio features essential tools like insulin pumps, continuous glucose monitoring (CGM) systems, infusion sets, specialized software platforms, and various supplementary accessories. These innovations are crafted to enable both patients and healthcare providers to accurately monitor and precisely regulate blood glucose levels. The enterprise was established in 1983 by Alfred E. Mann and is currently headquartered in Northridge, California.
MMED Company Deck
MMED Earnings Call
Q4 2026
0:00 / 0:00
MMED Stock 12 Month Forecast
Average Price Target
$21.60
▲(10.20% Upside)
Addus Homecare
―
Option Care Health
―
Brookdale Senior Living
―
National Healthcare
―
Aveanna Healthcare Holdings
―
Ownership Overview
0.71% Insiders
<0.01% Mutual Funds
0.14% Other Institutional Investors
98.25% Public Companies and
Individual Investors